We are a French pharmaceutical group that has been supporting healthcare professionals specialized in Diagnostic and Interventional Medical Imaging since 1926. We develop and market contrast media, delivery systems, medical devices and related solutions adapted to their needs. Guerbet is listed in Euronext Segment B, and a majority of its shares are owned by the Guerbet family.
Every second, somewhere in the world a patient undergoes an imaging procedure with a Guerbet product. More than 60,000 health professionals rely on our contrast agents to diagnose disease and assess treatment efficacy.
Lipiodol® was first discovered in 1901. In 1921 it became the first iodized contrast agent to be used in radiology. It serves today as “a standard of care” in interventional radiology.
Used for 30 years in clinical practice, more than 91 million* doses of Dotarem® have been injected in the world for MRI procedures.
*Data from March 2019
Our products and services are made available in more than 80 countries through our affiliates and network of distributors.
Advancing in innovative solutions is at the heart of Guerbet's mission and we dedicate 10% of our revenue to R&D*. We are focusing on the diagnosis of major diseases (cardiovascular diseases, cancers, diseases of the central nervous system) and interventional radiology. 395 patents are owned and pending*. 7 products have been launched in the last 2 years.
*at December 31, 2020
The success of Guerbet’s R&D is based on successful collaboration with worldwide scientific partners.
To meet its Research and Development targets, Guerbet is building a strategy of partnership and collaboration agreements. Thanks to this outward-looking approach, it is able to benefit from international scientific expertise. Medical imaging is a multi-disciplinary field requiring expertise in chemistry, physics, computing, image processing, electronics, biology and medicine.
Guerbet has acquired the facilities necessary for high-performance industrial production: 3 sites for the manufacture of the active pharmaceutical ingredients (APIs), 3 fill-and-finish facilities for our contrast agents, and 2 sites dedicated to imaging solutions (injectors, disposables) and services.
We manage the entire supply chain, from raw materials to delivery and end customers, so as to optimize turnaround times and costs while guaranteeing the highest end-to-end quality levels.
As of December 31, 2021, reported sales came to €732.1 million, up 2.8% from December 31, 2020 (€712.3 million), including an unfavorable forex impact of €16.4 million. Excluding forex effects and on a like-for-like basis, 2021 annual revenue was up 7.9% from 2020, and at the top range of the guidance communicated during the first half results presentation.